The U.S. FDA has finalized its rule to regulate laboratory-developed tests (LDTs) as medical devices, ending decades of enforcement discretion. This landmark decision imposes significant new requirements on clinical laboratories, aligning them with traditional IVD manufacturers and creating a new set of complex challenges for market access and compliance.

This shift will require labs to navigate a multi-year transition into full FDA compliance, including premarket reviews, quality system regulations, and post-market reporting. A university lab with a novel cancer diagnostic, for instance, now faces the daunting task of building a 510(k) submission and implementing a manufacturing-grade quality system, potentially stalling their innovation without expert regulatory guidance.

Key Takeaways:

- How does the FDA's five-year phase-in plan for LDTs affect my lab's current operations?

- What are the first steps to transition from CLIA compliance to FDA Quality System Regulation?

- Does my existing LDT qualify for any of the FDA's proposed grandfathering clauses?

- How can I build a regulatory strategy to prepare for a 510(k) submission?

- What new responsibilities will my lab have for post-market surveillance and adverse event reporting?

- Will this new rule create new opportunities for partnership with traditional IVD manufacturers?

- How can we leverage our existing clinical data to support a future premarket submission?

To learn more about navigating the new U.S. regulatory landscape or other global markets, contact us at [email protected], visit https://pureglobal.com/, or access our FREE AI tools and medical device database at https://pureglobal.ai/.